James B. Yu, MD
A recent emergence of data is showcasing the efficacy of moderate hypofractionation as a quicker way to administer radiation therapy in patients with prostate cancer, compared with the conventional radiation treatment. The novel method, according to James B. Yu, MD, may very well be on its way to an adoption as the new standard of care.
, Yu, associate professor of therapeutic oncology, and director, Prostate and Genitourinary Cancer Radiotherapy Program, at Yale Cancer Center, discussed the current data in support of using moderate hypofractionation in prostate cancer, as well as recent data showing how genomic testing can help with treatment decision making postoperatively.
OncLive: Can you give an overview of your talk on current and emerging standards in radiation therapy for prostate cancer?
: I talked about both current and emerging standards. Currently, the new standard with the most evidence behind it is something called moderate hypofractionation for prostate cancer. There’s been 3 randomized trials now showing that you can speed up the radiation treatment with equivalent cancer control.
The other topics I talked about were proton radiation, high-dose rate brachytherapy, prostate rectum spacing using something called a hydrogel gel, and finally, I talked briefly about genomic tests and their ability to help with decision making postoperatively—whether you should give radiation or not.
What data has there been so far in support of moderate hypofractionation?
There have been multiple randomized trials. The key trials are what is called noninferiority trials, which are trials that are trying to show that this new treatment is not inferior to the control treatment. These noninferiority trials need a lot more patients [than usual], so kudos to them for finishing them.
... to read the full story